Editorial Comment to Cancer‐Control Outcomes of Japanese Versus German Metastatic Hormone‐Sensitive Prostate Cancer Patients: A Real‐World Cross‐Country Comparison of Patients Undergoing Combination Therapies

Abstract

The treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) has changed substantially with the introduction of androgen receptor pathway inhibitors and docetaxel in addition to androgen deprivation therapy. Treatment options after progression to mCRPC have also expanded to include poly (ADP-ribose) polymerase inhibitors and prostate-specific membrane antigen-directed radioligand therapy. However, treatment patterns and access to these therapies vary across countries and healthcare systems [1]. In this issue